@t4Ji@i POSITIONS The BenMayInstitutefor CancerResearchandtheDepartmentof Surgeryat the Universityof Chicagoare seeking applicants for tenure-track positions at the Assistant or Associate Professor level with expertise in molecular oncology. Theidealcandidateswillbe an investigatorwiththe abilityto developan independentlyfundedresearchprogramin basic cancer biology, molecular genetics of cancers, or regulation of cell growth and differentiation. Candidates should havesufficientresearchexperienceto demonstratebothsignificantaccomplishmentsandoutstandingpotential. The faculty member is expected to take advantage of the extensive collaborative interactions available with members of the University genetics, biochemistry, immunology and molecular biology community. The Ben May Institute for Cancer Research (BMICR) is a basic research unit that for 45 years has been committed to the studyof basicmechanismsof cancerandimmunology.TheDepartmentof Surgeryhas a stronghistoryof research in the field of oncology. The BMICR and Surgery are closely interfaced with the University of Chicago NCI designated Comprehensive Cancer Center, the University of Chicago Center for Molecular Oncology and the Gwen Knapp Center for Lupus and Immunology Research. Additionally, these departments are closely affiliated with degree granting Committees on Immunology and Cancer Biology. Letters of recommendation including curriculum vitae, bibliography, a brief statement of research interest and the names of three references should be sent to: Jeffrey Bluestone, Chair, Search Committee, University of Chicago, 5841S. Maryland Ave.,MC6027,Chicago,IL 60637. THE UNIVERSITY OF CHICAGO Postdoctoral Research Fellowship Rapid Access to Intervention Development in Molecular Oncology “RAID― The Center for Molecular Medicine at the The NATIONALCANCERINSTITUTEis requesting applications for the University of Connecticut School of Medicine following initiative: Rapid Access to Intervention Development (RAID). invites applications for a postdoctoral fellow RAID will make available to academic investigators, on a competitive ship to (a) pursue novel approaches toward basis, the preclinical development contract resources of NCI ‘s Developmental Therapeutics Program. The goal of RAID is the rapid understanding the role of the cyclin Dl onco movement of novel molecules and concepts from the laboratory to the gene in human neoplasia and in relevant ani clinic for proof-of-principle clinical trials. RAID will assist investigators ma! models, and (b) exploit this understanding who submit successftil applications by providing any (or all) of the for therapeutic purposes. preclinical development steps that may be obstacles to clinical translation. These may include. for example, production, bulk supply, A strong background in molecular biology is GMP manufacturing, formulation, and toxicology. Suitable agents for RAID will include small molecules, biologics, or vaccines. There are required, and experience in molecular oncol two receipt dates for proposals per year@February 1 and August 1. ogy is highly desirable. Current applications must be received by February 1, with all materials submitted directly to the office listed below. For information on process Review of applications will begin on January and procedure. visit the web site, http://dtp.nci.nih.gov. Inquiries are 1, 1999, and will continue until the position is encouraged. and the opportunity to clarify issues or questions is filled. Send curriculum vitae, statement of re welcome. As of this cycle of applications. academic investigators may search experience and interests, and names of have collaborations with small-business partners and still qualify for RAID funding. Please note that a maximum oftwo distinct proposals per three references to: investigator can be submitted per the application review date. Please Dr. Andrew Arnold contact Director, Center for Molecular Medicine RAID, Office of Associate Director University of Connecticut School of Medicine Developmental Therapeutics Program, NCI Executive Plaza North, Suite 843 263 Farmington Avenue 6130 Executive Blvd., Rockville, MD 20852 Farmington, CT 06030.1316 Tel: 301.496.8720; Fax: 301.402.0831 Email: [email protected] Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 1996 American Association for Cancer Research. Cancer Research, Vol. 58, December 1, 1998 clinical research that are critical to addressing the current and looming crisis of cancer incidence, mortality, and health care costs.―In deter mining what it would take to expedite cancer research if adequate resources were made available, the Research Task Force gave serious consideration to key barriers that must be removed to accelerate progress against cancer, including those that contribute to the disproportionate effect of cancer on minority and medically underserved populations. The Research Task Force included leading scientists from the aca demic and private sectors, most of them members of the AACR. Thir teen subcommittees considered every aspect of cancer research, from the basic molecular biology of cancer to psychosocial research to unex plored opportunities in public-private partnerships. The findings of these subcommittees were then synthesized into the Report by Drs. Barker and Sigal. Dr. Barker, President and CEO of BIO-NOVA, Inc., is a leading member of the AACR, serving as Chairperson of its Public Education Committee since 1993. She is renowned for her effective leadership in public education, public policy, and science policy. For many years, she has worked actively to bring together scientists and consumer advocates in the fight against cancer. As a result of her vast knowledge in science and public issues, and her unflagging dedication, she has been very successful in forging synergistic relationships between these two impor tant sectors of the cancer community. Her unstinting passion about cancer and about the vital importance of research in accelerating pro gress against this disease has been the hallmark of her invaluable work in these areas. Dr. Sigal, President of Sigal Development, is a tireless advocate for cancer research. The eradication of cancer is a primary mission in Dr. Sigal's philanthropic and public pursuits. She founded and serves as Chairman of the Board of Friends of Cancer Research; this organization was formed to acknowledge the 25th Anniversary of the National Cancer Act and to emphasize the importance of cancer research in the conquest of this disease. She currently serves as President of the Creative Corn munity Task Force for Cancer Research. She was a Presidential ap pointee to the National Cancer Advisory Board from 1992-98, and she served as Chair of the Budget and Planning Committee of the Board for over five years. Dr. Sigal is highly respected by cancer researchers for her many years of leadership and her unwavering personal commitment (CANCER RESEARCH 58. 5263-5266. December i, i998J Advances in Brief Angiogenesis in the Hollow Fiber Tumor Model Influences Drug Delivery to Tumor Cells: Implications for Anticancer Drug Screening Programs1 Roger M. Phillips,2Jennifer Pearce, Paul M. Loadman, Michael C. Bibby, Patricia A. Cooper, David J. Swaine, and John A. Double Clinical Oncology Unit, Universityof Bradford, Bradford, BD7 IDP, United Kingdom Abstract unlikely that drug delivery problems would occur after an i.p. drug administration. Responses at the s.c. site after i.p. drug administration, The National Cancer Institute uses the hollow fiber assay as part of its however, may indicate that the new agent possesses both good bio screening program for anticancer drug discovery. Angiogenesis to hollow availability and pharmacological properties. Drug delivery to tumors fibers Implanted s.c. has not been reported, thereby raising concerns about the efficiency of drug delivery and Its subsequent effects on chemo is dependent on several factors, one of which is the presence of an sensitivity. By extending postimplantation times beyond the 6-day period established blood supply. Blood vessel development to hollow fibers presently used, extensive vascular networks develop, resulting in both implanted s.c. has not been reported previously, raising concerns increased delivery and chemosensitivity to doxorubicin. This study sug about the efficiency of drug delivery and the subsequent effects this gests that present protocols used to evaluate compounds may produce may have on chemosensitivity, bearing in mind the role that drug false negative results, and additional studies to determine the predictive C X T values play in determining chemosensitivity (9). Lack of value of the assay are required. activity at the s.c. site may, therefore, be caused by poor drug delivery as a result of lack of blood vessel development; if this is the case, the Introduction validity of the test system is called into question. Tumor cells in In the late 1980s, the Developmental Therapeutics Program of the hollow fibers should theoretically be able to induce an angiogenic NCI3 radically changed its approach to the large-scale, random response as the molecular weight cutoff point of the fiber walls is screening of compounds for anticancer activity (1). Instead of using large enough (Mr 500,000) to allow for appropriate growth factors to xenografts or syngeneic rodent tumor models as a front line screen, all pass through the fiber wall. Present protocols for using the hollow compounds submitted to the NC! are evaluated against a panel of fiber assay involve